Výsledky vyhledávání

Akademický článek

Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses

Autor: Richard S. Matulewicz, Fady Baky, Andrea Knezevic, Joel Sheinfeld, Brandon M. Williams, Rachel E. Kantor, Nicole Liso, Jahwa Hossain, Maria Bromberg, Alisa Valentino, Rachel So, Samuel A. Funt, Fei Ye, Darren R. Feldman

Publikováno v: European Urology Open Science, Vol 68, Iss , Pp 1-9 (2024)

Background: MicroRNAs (miRNAs) show promise as blood-based tumor markers for germ cell tumors (GCTs), with miRNA-371-3p being the most studied. The marginal benefit of including other candidate miRNAs to aid with the management of testicular GCTs rem

Externí odkaz: https://doaj.org/article/57a3806f22b54971b715cd62cc504717

Zobrazit plný text záznamu

Akademický článek

Autor: Steven R. Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadło-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee Rho

Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

Introduction SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.Methods Subjects were randomized to receive 45 mg of SB17 or UST

Externí odkaz: https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041

Zobrazit plný text záznamu

Akademický článek

Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Autor: Giampiero Girolomoni, Steven R. Feldman, Alexander Egeberg, Luis Puig, Jinah Jung, Hojung Jung, Younju Lee

Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

Background SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate-to-severe chronic plaque psoriasis.Objectives To assess the four-year persistenc

Externí odkaz: https://doaj.org/article/886895337c754049b2e0686f0091cc8e

Zobrazit plný text záznamu